Promise and Implementation of Proteomic Prostate Cancer Biomarkers

Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of “big data” and “personalized medicine” proteomics-based biomarkers hold great promise to provide clinically applicable tools, as proteins regulate all biological functions, and integrate genomic information with the environmental impact. In this review article, we aim to provide a critical assessment of the current proteomics-based biomarkers for prostate cancer and their actual clinical applicability. For that purpose, a systematic review of the literature published within the last 10 years was performed using the Web of Science Database. We specifically discuss the potential and prospects of use for diagnostic, prognostic and predictive proteomics-based biomarkers, including both body fluid- and tissue-based markers.

Abstract licence: CC BY

1. 6.

   Identification of prostate cancer biomarkers in urinary exosomes · 2015

2. 42.

   Proteomic Profiling of Exosomes Leads to the Identification of Novel Biomarkers for Prostate Cancer · 2013

3. 50.

   Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness · 2014

4. 57.

   Implementation of proteomic biomarkers: making it work · 2012

5. 66.

   Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort · 2012

6. 68.

   Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration · 2012

7. 73.

   Advances in mass spectrometry-based clinical biomarker discovery · 2016

8. 93.

   Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer · 2017

100 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.